Title
A human liver chimeric mouse model for non-alcoholic fatty liver disease.

Permalink
https://escholarship.org/uc/item/2hg8h2x9

Journal
JHEP reports : innovation in hepatology, 3(3)

ISSN
2589-5559

Authors
Bissig-Choisat, Beatrice
Alves-Bezerra, Michele
Zorman, Barry
et al.

Publication Date
2021-06-01

DOI
10.1016/j.jhepr.2021.100281

Peer reviewed
A human liver chimeric mouse model for non-alcoholic fatty liver disease

Authors
Beatrice Bissig-Choisat, Michele Alves-Bezerra, Barry Zorman, Scott A. Ochsner, Mercedes Barzi, Xavier Legras, Diane Yang, Malgorzata Borowiak, Adam M. Dean, Robert B. York, N. Thao N. Galvan, John Goss, William R. Lagor, David D. Moore, David E. Cohen, Neil J. McKenna, Pavel Sumazin, Karl-Dimiter Bissig

Correspondence
karldimiter.bissig@duke.edu (K.-D. Bissig).

Graphical abstract

Highlights
- Human liver chimeric mice fed a western diet develop NAFLD.
- Within the same chimeric liver, human hepatocytes developed pronounced steatosis while murine hepatocytes remained normal.
- Unbiased metabolomics and lipidomics of fatty humanised mouse livers revealed signatures of clinical NAFLD.
- Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes.
- This humanised NAFLD model is a physiologically relevant, experimentally tractable model for the study of steatosis.

Lay summary
Fatty liver disease is an emerging health problem, and as there are no good experimental animal models, our understanding of the condition is poor. We here describe a novel humanised mouse system and compare it with clinical data. The results reveal that the human cells in the mouse liver develop fatty liver disease upon a Western-style fatty diet, whereas the mouse cells appear normal. The molecular signature (expression profiles) of the human cells are distinct from the mouse cells and metabolic analysis of the humanised livers mimic the ones observed in humans with fatty liver. This novel humanised mouse system can be used to study human fatty liver disease.

https://doi.org/10.1016/j.jhepr.2021.100281
A human liver chimeric mouse model for non-alcoholic fatty liver disease

Beatrice Bissig-Choisiat,1,2† Michele Alves-Bezerra,2,† Barry Zorman,3 Scott A. Ochsner,4 Mercedes Barzi,1 Xavier Legras,1 Diane Yang,4 Malgorzata Borowiak,5,5 Adam M. Dean,4 Robert B. York,4 N. Thao N. Galvan,6 John Goss,1 William R. Lagor,2 David D. Moore,4 David E. Cohen,1 Neil J. McKenna,4 Pavel Sumazin,1 Karl-Dimiter Bissig

1Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, USA; 2Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, USA; 3Texas Children’s Cancer Center, Division of Pediatrics, Baylor College of Medicine, Houston, TX, USA; 4Institute for Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University, Poznan, Poland; 5Department of Surgery, Texas Children’s Hospital, Houston, TX, USA; 6Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA; 7Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center, Duke University, Durham, NC, USA; 8Department of Gastroenterology, Department of Medicine, Duke University, Durham, NC, USA; 9Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA; 10Duke Cancer Institute, Duke University, Durham, NC, USA

JHEP Reports 2021. https://doi.org/10.1016/j.jhepr.2021.100281

Background & Aims: The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and animal studies, our understanding of NAFLD pathogenesis remains limited. To better study the molecular changes driving the condition we aimed to generate a humanised NAFLD mouse model.

Methods: We generated TIRF (transgene-free Il2rg-/-/Rag2-/-/Fah-/-) mice, populated their livers with human hepatocytes, and fed them a Western-type diet for 12 weeks.

Results: Within the same chimeric liver, human hepatocytes developed pronounced steatosis whereas murine hepatocytes remained normal. Unbiased metabolomics and lipidomics revealed signatures of clinical NAFLD. Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes, demonstrating stark species differences in liver function. Regulatory network analysis indicated close agreement between our model and clinical NAFLD with respect to transcriptional control of cholesterol biosynthesis.

Conclusions: These NAFLD xenograft mice reveal an unexpected degree of evolutionary divergence in food metabolism and offer a physiologically relevant, experimentally tractable model for studying the pathogenic changes invoked by steatosis.

Introduction

The global spread of high-fat, high-sugar diets and sedentary lifestyles carries with it a sharp rise in non-alcoholic fatty liver disease (NAFLD).1 Hepatic steatosis is considered problematic because it leads to inflammation and fibrosis, creating the more serious condition known as non-alcoholic steatohepatitis (NASH).2,3 NASH in turn triggers compensatory cell proliferation, increasing the risk of hepatocellular carcinoma (HCC), which has become the second leading cause of cancer deaths.4 Given that steatosis seems to drive pathogenesis in all these major diseases, there is a pressing need to understand how it changes liver function.

NAFLD has been extremely difficult to study in either human patients or mice. Although transcriptomic, lipidomic, and metabolic profiling studies of human livers are numerous, clinical approaches are generally retrospective and human participants are not experimentally tractable. Studies using murine models present different limitations: genetic models of NAFLD based on single-gene alterations, such as the ob/ob or db/db obese mouse strains, may not accurately reflect the typically...
polygenic human situation. Dietary models gain weight, develop steatosis, and become insulin-resistant, but exhibit much less liver injury than human NASH patients, suggesting fundamental differences in rodent and human livers. Indeed, metabolic profiling of rats fed a methionine-choline-deficient diet—which inhibits fatty acid oxidation, thereby leading to NASH—identified species differences in bile acid, insulin, and leptin levels, limiting this model’s utility for studies of biomarkers or disease progression.

Having recently developed human liver chimeric mice to study human drug metabolism,7 we took a similar approach here to study NAFLD. We demonstrate that humanised TIRF (transgene-free, I2rg−/−, Rag2−/−, Fah−/−) mice develop NAFLD when fed a Western-type high fat/high sucrose diet (WD). Metabolic and histological changes of human hepatocytes in xenograft mice resemble those found in human NAFLD, whereas the molecular signatures of the human and murine hepatocytes within the same chimeric livers differ greatly. This chimeric mouse model therefore offers an ideal platform for studying the response of human hepatocytes to diet-induced NAFLD.

**Materials and methods**

**Animals and diets**

The TIRF strain was generated by CRISPR/Cas9 deletion of the 3 genes in mouse zygotes as we described previously and crossing out the P450 oxidoreductase (Por) gene from the PIRF (Por−/−, I2rg−/−, Rag2−/−, Fah−/−) strain. Human hepatocytes (1 × 10⁶ per mouse) were transplanted by splenic injection into the livers of 3-week-old male and female TIRF mice maintained on the drug nitisinone (NTBC) from the splenic injection into the livers of 3-week-old male and female TIRF mice maintained on the drug nitisinone (NTBC) from the drinking water as previously described. Immediately after transplantation, we applied selection pressure toward transplanted chimeric human hepatocytes (CHHs) by step-wise reduction and withdrawal of NTBC. Human albumin (hALB) levels (ELISA, Bethyl Laboratories, Inc., Montgomery, TX, USA) in the plasma of transplanted mice was measured to gauge the extent of chimerism. Only mice with >70% human liver chimerism were used and put on NTBC (no tyrosinemic stress of murine hepatocytes) for the remainder of the study.

Humanised mice were fed normal chow (NC) (2019 Teklad global 19% protein extruded rodent diet, Envigo, Madison, Wisconsin USA) or WD (D12079B, RD Western Diet, Research Diets, New Brunswick, New Jersey, USA) for 12 weeks. Mice were euthanised after a 6-h fast and plasma was collected. Livers were then harvested and snap-frozen in liquid nitrogen and stored at -80°C. All animal experiments were approved by the Institutional Animal Care and Use Committee. Animals received humane care according to the criteria outlined in the NIH Guide for the Care and Use of Laboratory Animals.

**Metabolic and lipidomic analyses**

Sample preparation and analysis for global metabolomics was carried out at Metabolon Inc. (Durham, NC, USA) as described by Hatori et al., with modifications (see Supplementary Methods). Lipids for untargeted lipidomics were extracted from snap-frozen liver samples at Metabolon Inc. using dichloromethane and methanol in the presence of deuterated internal standards. Details for extraction and analysis can be found in the Supplementary Methods.

**RNA-sequencing, data processing, and NAFLD consensome analysis**

Whole-transcriptome RNA-sequencing (RNA-Seq) was performed using total RNA isolated using a PureLink RNA mini kit (Invitrogen PureLink RNA Mini Kit, ThermoFisher Scientific, USA). RNA-seq read pairs were aligned to a combined human (hg38) and mouse (mm10) genome using STAR version 2.7.1a. RNA-Seq data is available from European Nucleotide Archive, ENA accession code (PRJEB35014). See Supplementary Methods for details of library generation and gene expression quantification.

To generate the human NAFLD consensome, we first retrieved a total of 9 Gene Expression Omnibus clinical NAFLD or NASH case-control transcriptomics datasets (Table S6, section 3) (see Supplementary Methods). Differential expression values were committed to the consensome analysis pipeline as previously described. Panther and Reactome pathway analysis was used to evaluate enrichment of biological processes in NAFLD consensome confidence transcripts (CTs) or H:M>1.2 genes. Node high confidence transcriptional target (HCT) intersection analysis was performed as previously described.

Additional methods are described in the Supplementary Methods.

**Results**

**Human liver chimeric mice develop steatosis after 12 weeks on a WD**

To evaluate the susceptibility of xenograft mice to diet-induced NAFLD, we developed the TIRF strain. In contrast to previous Fah−/−/Rag2−/−/Il2rg−/− mice, this strain has no neomycin-resistance cassette that could confound results in several ways. The neomycin phosphotransferase gene can influence the metabolism of transgenic mice; the transgene can alter gene expression and has been shown to increase expression of both c-myc and various liver genes; and it was shown to reduce fructose 2,6-bisphosphate and lactate in fibroblasts.

Three-week-old male and female TIRF mice were humanised by splenic injection of human hepatocytes from 1 of 3 different healthy human donors (Fig. 1A). Three to 4 months after transplantation, human chimerism was assessed by measurement of hALB in the murine plasma and only mice with >70% human hepatocytes were used in subsequent studies. Mice bearing human hepatocytes were randomised and fed either WD or NC for 12 weeks (Fig. 1A). To mimick low mitotic index of the human liver, we removed selection pressure for human hepatocytes in humanised mice (see Methods for details).

Relative to NC, WD induced no significant change in body or liver weight (Fig. 1B and C), blood chemistries (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transpeptidase; Fig. 1D) or fasting levels of plasma triacylglycerols or glucose over the 12-week period. Plasma cholesterol, however, increased 70% (Fig. 1E). This is consistent with observations from patients with NAFLD, where intrahepatic fat accumulation occurs before the development of obesity or abnormalities in standard liver function tests. As no selection pressure for human hepatocytes was applied, we compared hALB levels before and after 12 weeks on WD, respectively, with NC. There was no significant decrease on NC, but WD decreased the human albumin levels from an average of 4.8 mg/ml to 2.2 mg/ml (Fig. 51).

**Note:** The research article titled “Human liver chimeric mice develop steatosis after 12 weeks on a WD” from JHEP Reports 2021, vol. 3, 100281, is referenced in this text. The author details are not included here. However, the key findings and methodology related to the development of human liver chimeric mice to study human drug metabolism and NAFLD are highlighted. The article discusses the use of human liver chimeric mice to study human drug metabolism, NAFLD, and the use of CRISPR/Cas9 deletion to generate the TIRF strain. The article also details the dietary model used (Western-type high fat/high sucrose diet) and the metabolic and histological changes observed in humanised TIRF mice fed a Western diet.
We next examined histological changes in livers of humanised mice in response to 12 weeks of WD. H&E staining identified pronounced macrovesicular steatosis with microvesicular components (Fig. 2A and B). Immunostaining for fumarylacetoacetate hydrolase (FAH) confirmed that steatosis was confined to human hepatocytes, repopulating across the whole liver acinus (Fig. 2A and C). Oil-Red-O staining further confirmed lipid accumulation (Fig. S2). Staining for connective tissue (Trichrome Masson) and the liver-resident macrophages (Kupffer cells, F4/80), did not show appreciable differences between murine and human regions of the chimeric livers (Fig. 2A).

Collectively, these findings indicate that humanised TIRF mice develop human hepatocyte-specific steatosis after 12 weeks of WD, replicating early clinical NAFLD.

**Distinct hepatic metabolite profiles between NAFLD and control xenograft mice**

Because livers of patients with NAFLD undergo profound metabolic changes in comparison with livers of patients without steatosis, we searched for similar effects in WD-fed humanised mice. Using global metabolomic profiling, we found that among 565 identified metabolites, 48 were significantly increased and 59 were significantly decreased in livers of NAFLD chimeric mice compared with controls (Table 1 and S1). Among metabolites with the largest increases were cholesterol, 4-cholesten-3-one (an intermediate in the synthesis of bile acids) and the antioxidant α-tocopherol (Table 1 and S1). Metabolic pathway enrichment analysis showed WD-induced increases in hepatic concentrations of long-chain and branched free fatty acids (FFAs), intermediates of endocannabinoid, sphingosine, and acylcholine metabolism (Fig. 3A and C). In contrast, we observed WD-induced decreases in levels of metabolites associated with xenobiotic metabolism, vitamin A, and benzoate (Table 1 and Fig. 3B and C), which have been previously found to be reduced in patients with NAFLD. Similarly, WD decreased levels of polyunsaturated free fatty acid (PUFA) species (Table 1 and S1) and dihydroxy fatty acid (FA) lipid peroxide markers (Table 1 and S1). Conversely, the WD induced increases in levels of docosatrienoate and mead acid (Table 1).

**Humanised mouse livers have lipid profiles similar to those of patients with NAFLD**

Accumulating evidence suggests that NAFLD progression is associated with changes in hepatic lipid species composition and concentration. The observation that levels of FFA species were altered in livers of WD-fed humanised mice prompted us to evaluate whether this would be reflected in changes in the overall hepatic lipid profile. Although most studies have used targeted analysis, we used untargeted lipidomics and found increased steady-state concentrations of cholesteryl esters (CEs), diacylglycerols (DAGs), triacylglycerols (TAGs), ceramides (CErs), and lactosylceramides (LCERs) in livers of WD-fed chimeric mice in comparison with NC-fed counterparts (Fig. 4A and Table S2).

We next examined the influence of the WD in the composition of FAs that are esterified to complex lipids in livers of xenograft mice. The composition of FFAs as well as FAs in DAG, TAG, and lysophosphatidylethanolamine exhibited increased odd, satuared, and monounsaturated fatty acid (MUFA) species, along with decreased PUFAs (Fig. 4B), resembling livers of patients with NAFLD. In the chimeric mice, hepatic steatosis
MUFAs, with an overall decrease in saturated and PUFA species (Table S2). Sphingolipids reflected a preference for the esterification of medium- to long-chain saturated FAs and MUFAs, along with decreased esterification of very long-chain saturated FAs (Fig. 4B).

Mouse and human hepatocytes of NAFLD xenograft mice exhibit different transcriptional profiles

To determine whether changes in hepatic metabolites and lipids could be attributable to altered transcriptional profiles in the NAFLD model, we performed a transcriptional analysis of CHHs in NC- and WD-fed chimeric mice. We identified a total of 681 differentially expressed genes (DEGs) when comparing WD-fed with NC-fed chimeric mice (Fig. 5A and B, Table S3 and S4). Pathway enrichment analysis revealed that upregulated genes (52 genes; 7.6% of total DEGs) were predominantly associated with lipid metabolism and amino acid catabolism, whereas downregulated genes (629 genes; 92.4% of total DEGs) were primarily related to cholesterol metabolism, including cholesterol biosynthesis and sterol regulatory element-binding proteins (SREBP)-regulated genes (Fig. S3, Table S3 and S4).

Next, we analysed the transcriptional profile of chimeric murine hepatocytes (CMHs) in the same groups of chimeric mice. Upon WD feeding, mouse hepatocytes exhibited a total of 1,196 DEGs in comparison to NC-fed controls (Fig. 5C, Table S3 and S5). Notably, mouse DEGs showed little overlap with human DEGs. Among 87 upregulated mouse genes (7.3% of total DEGs), only 2 were also upregulated in human hepatocytes (Arsb/ARSB and Fatp2/SLC27A2) (Fig. 5D). Similarly, 1,109 mouse orthologues were shown to be downregulated (92.7% of total DEGs), from which only 92 genes were also identified among downregulated human orthologues (Fig. 5D). These findings indicate that, in the setting of hepatic steatosis, the mouse hepatocyte transcriptional signature markedly differs from the human counterparts.

Alignment of cholesterol biosynthesis transcriptional networks between xenograft human hepatocytes and clinical NAFLD

Given the abundant evidence connecting cholesterol metabolism to NAFLD, we next explored transcriptional mechanisms that might contribute to the marked rise in plasma and hepatic cholesterol levels observed in chimeric mice upon WD-feeding (Fig. 1E and Table S1). We generated a list of transcripts that were differentially expressed (P < 0.05) in response to WD in both CHHs and CMHs, and had relative CHH:CMH expression levels that exceeded 20% (H:M>1.2; Table S6, section 1). Pathway analyses of this gene set reflected significant enrichment of genes mapped to cholesterol biosynthesis and SREBP-regulated gene expression (Fig. 6A). Closer inspection of the H:M>1.2 transcripts indicated that 6 represented de novo cholesterol biosynthesis pathway enzyme genes (CBPPEGs; Fig. 6B and Table S6, sections 1 and 2). Notable among these were squalene epoxidase (SQLE), which catalyses the rate-limiting conversion of squalene to 2,3-oxidosqualene, and dehydrocholesterol reductase 7 (DHCR7), the terminal enzyme in the Kandutsch-Russell pathway for cholesterol synthesis. Although CBPPEGs were repressed in both CMHs and CHHs in response to WD-feeding, this downregulation was much less efficient in CHHs, such that CBPPEGs were expressed at levels up to 2.4-fold higher in CHHs relative to CMHs (Fig. 6B and Table S6, section 2).

Fig. 2. Diet-induced steatosis is associated with human hepatocytes in NAFLD xenograft mice. Histological analyses were performed in liver sections after 12 weeks of Western-type diet (n = 6–8 per group). (A) Representative images of H&E-, fumarylacetoacetate hydrolase (FAH)-, Trichrome Masson-stained and F4/80-immunostained liver sections. Scale bar = 50 μm. (B) Representative image of H&E-stained liver sections showing separation of hepatocytes from human or murine origin (dotted line). Scale bar = 50 μm. (C) Quantification of macro- and microvesicular steatosis in human and murine liver tissue. Percentage surface area of multiple lobes (2–5) of NAFLD xenograft mice (n = 6) are given with whiskers for the range of non-steatotic human or murine hepatocytes (see methods for details). NAFLD, non-alcoholic fatty liver disease.

coincided with increases in all analysed FA species esterified to CE (Fig. 4B). However, monoacylglycerols (MAGs) and glycerophospholipids showed increased esterification of odd FAs and MUFAs, with an overall decrease in saturated and PUFA species (Fig. 4B), an effect that was more pronounced in n-3 PUFA species (Table S2). Sphingolipids reflected a preference for the esterification of medium- to long-chain saturated FAs and MUFAs, along with decreased esterification of very long-chain saturated FAs (Fig. 4B).
We next evaluated the extent to which elevated expression levels of CBPEGs in the CHHs relative to the CMHs reflected clinical NAFLD. Using our previously-described consensome algorithm, we generated a clinical NAFLD transcriptomic consensome (Fig. 6C), which ranks ~18,100 human genes according to the frequency with which they are upregulated or downregulated across 22 independent published clinical NAFLD case-control transcriptomic datasets (Table S6, sections 2 and 3).

Fig 3. NAFLD xenograft mouse livers show altered metabolic profile after 12 weeks on WD. Global metabolic profiles were determined in livers of 12 week WD or NC chimeric mice (n = 8 per group). (A) Metabolite species increased in livers of NAFLD xenograft mice after 12 weeks of WD. (B) Metabolite species decreased in livers of NAFLD xenograft mice after 12 weeks on WD. (C) Relative levels of individual metabolites are shown. FA, fatty acid; NAFLD, non-alcoholic fatty liver disease; NC, normal chow; PUFA, polyunsaturated fatty acid; WD, Western-type diet.
Validating the NAFLD consensome, a 25-gene signature recently published by Govaere et al. predicts clinical NAFLD severity was robustly enriched among mean FC=1.25 clinical NAFLD CTs (Q=0.05) in the consensome (GOVAERE: OR = 12.3, \(p=4\times10^{-6}\); Fig. 6D and Table S6, section 2). Confirming the xenograft mouse as an accurate model of clinical NAFLD, we identified a very strong enrichment of the 6 CBPEGs (Fig. 6B) among the same set of clinical NAFLD CTs (CPBEGs: OR = 27, \(p=4\times10^{-6}\); Fig. 6C). Taken together, these data demonstrate a robust convergence between the elevated expression of CBPEGs in clinical NAFLD and in steatotic CHHs in the chimeric mice.

We next wished to gain insight into the extent to which transcriptional drivers of the xenograft model CBPEGs aligned with those implicated in human clinical NAFLD. To investigate this, we performed node HCT intersection analysis, which generates statistical measures of intersections between a given set of genes and HCTs for cellular signalling pathway nodes. For HCT intersection analysis, we computed intersections between the same set of clinical NAFLD and in steatotic CHHs in the chimeric mice.

Discussion

Our goal in this study was to establish and characterise a mouse model that faithfully replicated the pathophysiology of human NAFLD. Our humanised TIRF mice recapitulate histological, metabolic and transcriptional features of human NAFLD after 12 weeks on WD, with steatosis being confined in large to the human hepatocytes.

There were several similarities between lipid profiles in the NAFLD xenograft mice and patients with NAFLD. Free cholesterol and triacylglycerol lipid classes are increased both in livers of patients with NAFLD and NAFLD xenograft mice, as are hepatic concentrations of cholesteryl esters, which supports the role of these lipids in the pathogenesis of NAFLD. Multiple

Table 1. Top differentially regulated metabolites in NAFLD xenograft mice. *Humanised mice on WD (NAFLD) compared with humanised mice on normal chow (control). NAFLD, non-alcoholic fatty liver disease; WD, Western-type diet.

| Metabolite                        | Pathway                               | p value | Fold change (NAFLD vs. control*) |
|-----------------------------------|----------------------------------------|---------|---------------------------------|
| **Increased**                     |                                        |         |                                 |
| Docosatrinooate (22:3n6)          | Polysaturated fatty acid (n3 and n6)   | 1.12E-02| 12.50                           |
| Mead acid (20:3n9)                | Polysaturated fatty acid (n3 and n6)   | 4.56E-04| 11.95                           |
| (14 or 15)-methylpalmitate (a17:0 or i17:0) | Fatty acid, Branched                | 3.89E-03| 10.10                           |
| 1-oleoyl-GPG (18:1)               | Lyso phospholipid                     | 8.93E-03| 9.18                            |
| 10-heptadecenoate (17:1n7)       | Long chain fatty acid                 | 1.46E-03| 5.44                            |
| 10-nonadecenoate (19:1n9)        | Long chain fatty acid                 | 3.41E-06| 4.74                            |
| Myristoleate (14:1n5)             | Long chain fatty acid                 | 1.58E-02| 4.24                            |
| N-oleoyltaurate                   | Endocannabinoid                       | 2.99E-02| 3.97                            |
| Pentadecanoate (15:0)             | Long chain fatty acid                 | 1.71E-02| 3.76                            |
| Eicosenoate (20:1)                | Long chain fatty acid                 | 1.64E-04| 3.53                            |
| Oleoylcholine                     | Fatty acid metabolism (acyl choline)  | 2.68E-02| 3.26                            |
| (16 or 17)-methylstearate (a19:0 or i19:0) | Fatty acid, branched                 | 4.60E-06| 3.09                            |
| Heptadecaposphingosine (d17:1)    | Sphingosines                          | 1.29E-03| 3.02                            |
| Palmitoleate (16:1n7)             | Long chain fatty acid                 | 9.18E-04| 2.81                            |
| 1-oleoyl-GPS (18:1)               | Lyso phospholipid                     | 1.94E-02| 2.54                            |
| **Decreased**                     |                                        |         |                                 |
| Homostachydrine                   | Food component/Plant                  | 3.64E-04| 0.01                            |
| Stachydrine                       | Food component/Plant                  | 3.99E-04| 0.02                            |
| Docosatrienoate (22:3n6)          | Polysaturated fatty acid (n3 and n6)   | 1.46E-05| 0.02                            |
| Trigoneline (N-methylnicotinate)   | Nicotinate and nicotinamide metabolism| 1.30E-03| 0.03                            |
| Histidine betaine (hercynine)     | Food component/Plant                  | 4.89E-05| 0.08                            |
| 4-guanidinobutanoate              | Guanidino and acetamido metabolism    | 9.09E-03| 0.10                            |
| N,N,N-trimethyl-5-amineovaleriate | Lysine metabolism                     | 8.95E-03| 0.15                            |
| Cis-4-deceneoate (10:1n6)         | Medium chain fatty acid               | 9.88E-06| 0.17                            |
| Carotene diol (1)                 | Vitamin A metabolism                  | 3.22E-03| 0.21                            |
| Ergothioneine                     | Food component/plant                  | 7.38E-05| 0.21                            |
| 13-HODE + 9-HODE                  | Fatty acid, monohydroxy              | 1.65E-02| 0.21                            |
| 3-sulfo-L-alanine                 | Methionine, cysteine, S-adenosylmethionine| 1.44E-02| 0.22                            |
| P-cresol glucuronide              | Tyrosine metabolism                   | 2.59E-03| 0.24                            |
| 4-hydroxy-nonenal-glutathione     | Glutathione metabolism                | 6.13E-03| 0.25                            |
| Gamma-tocopherol/beta-tocopherol  | Tocopherol metabolism                 | 5.01E-04| 0.27                            |
studies have suggested that PUFA depletion also contributes to the pathogenesis of human NAFLD. Obese NAFLD patients exhibit marked decreases in hepatic concentrations of n-3 PUFAs, and two mechanisms have been proposed to explain this observation: (i) an increased utilisation of n-3 PUFAs owing to the high oxidative status, and (ii) a reduced capacity for desaturation of α-linoleic acid (18:3n-3; a precursor of n-3 PUFAs) owing to decreases in hepatic activities of Δ-5 and Δ-6 desaturases. In line with this, livers of chimeric mice showed lower concentrations of PUFAs along with a trend towards downregulated expression of FADS1 and FADS2 genes, which encode human Δ-5 and Δ-6 desaturases. In hepatic PUFA content are thought to influence hepatic lipid homeostasis by regulating transcription factors such as PPARα and SREBP1c. Under normal circumstances, PUFAs act as activators of PPARs and inhibitors of SREBP1c, thereby promoting FA oxidation at the expense of lipogenesis, but in livers of obese patients with NAFLD, PUFA depletion correlates with reduced mRNA levels of PPARα and increased SREBP1c, potentially leading to a pro-lipogenic program that exacerbates the intrahepatic lipid accumulation in these patients. Although PPARα mRNA levels remained unchanged in the conditions tested in the present work, human liver chimeric mice recapitulated the increase in SREBP1c gene expression, further supporting the involvement of this transcription factor in early stages of human NAFLD. A unique feature of NAFLD xenograft mice is the ability to discern transcriptional discrepancies between human and mouse hepatocytes exposed to identical nutritional challenges within chimeric livers. Illustrating this, we identified 6 CPBEs that were highly repressed in response to WD in CMHs, but to a lesser extent in CHHs. Using a reduced-bias consensome meta-analysis of published NAFLD transcriptomic datasets, we demonstrated that the elevated expression of CBPEs in CHHs relative to CMHs closely reflected the relative expression levels of their human orthologs between clinical NAFLD and normal livers. The gene with the highest CHH:CMH ratio (2.4), and the highest ranked CBPEG in the NAFLD consensome (23rd of 18,162 genes) was SQLE, whose expression has been connected to the pathogenesis of hepatic steatosis and its subsequent progression to hepatocellular carcinoma. Indeed, the identification of squalene epoxidase as a major mediator of increased hepatic biosynthesis of cholesteryl esters represents a plausible explanation for the elevated levels of

---

Fig 4. Altered lipid profile in livers of NAFLD xenograft mice. Global lipid profiles were determined in livers of 12-week WD or NC chimeric mice (n = 8 per group). (A) Hepatic levels of lipids. *p < 0.05, **p < 0.01, and ***p < 0.001 using Welch’s t-test. (B) Hepatic fatty acyl composition (relative to NC-fed humanised mice). Grey boxes, data not available. CE, cholesteryl ester; CER, ceramide; DAG, diacylglycerol; DCE, dihydroceramide; FFA, free fatty acid; LCER, lactosylceramide; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; MAG, monoglyceride; NAFLD, non-alcoholic fatty liver disease; NC, normal chow; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; TAG, triacylglycerol; WD, Western-type diet.
Fig 5. Divergent transcriptional responses to WD between CHHs and CMHs in NAFLD xenograft mice. Transcriptomic analysis of human (A and B) and mouse (C and D) hepatocytes was performed in livers of 12 week WD or NC chimeric mice (n = 8 per group). Upregulated genes in the WD-fed mice relative to the NC group are shown in red, downregulated genes are in blue. (D) Groupwise comparison of differentially expressed mouse and human genes (WD vs. NC). CHHs, chimeric human hepatocytes; CMHs, chimeric mouse hepatocytes; NC, normal chow; NAFLD, non-alcoholic fatty liver disease; WD, Western-type diet.

Fig 6. Distinct human and mouse cholesterol biosynthesis enzyme expression profiles in chimeric livers recapitulate clinical NAFLD. (A) Enrichment of SREBP1-cholesterol biosynthesis transcriptional pathways connects chimeric human hepatocytes (CHHs) and clinical NAFLD. (B) H:M >1.2 genes encode enzymes in the de novo cholesterol biosynthesis pathway. Enzyme names are shown in (D). Red numerals refer to CHH:CMH relative expression ratios. (C) The human NAFLD transcriptomic consensome ranks 18,162 genes based on their discovery rates across 20 independent, publicly archived clinical NAFLD case:control transcriptomic datasets. Hypergeometric test statistics for over-representation of the 25-gene NAFLD severity signature (GOVAERE) and CPBEGs among NAFLD CTs (mean case: control FC >1.25) are indicated. Q, FDR-corrected consensome p-value. (D) Node HCT intersection analysis of CPBEGs and FC >1.2 Q <0.05 clinical NAFLD consensome genes. NAFLD UP INT Q<0.05: nodes with significant (Q <0.05) intersections with NAFLD consensome CTs with mean case: control FC>1.2. CPBEGs INT Q <0.05: nodes with significant (Q <0.05) intersections with CPBEGs. Full data are in Table S6, section 4. CPBEG, cholesterol biosynthesis pathway enzyme genes; FC, fold change; FDR, false discovery rate; HCT, high confidence transcriptional target; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; SREBP1, sterol regulatory element-binding protein 1.
these lipid species in livers of WD-fed chimeric mice. Finally, we identified robust evidence for convergence between transcriptional drivers of CPBE expression and those regulating expression of genes consistently induced in clinical NAFLD.

In addition to its strengths, our NAFLD xenograft model has some limitations. Human albumin levels reveal a slight but significant decrease in humanisation after 12 weeks of WD feeding. Although this might constitute an experimental limitation particularly if animals do not have a high human liver chimism, this observation is neither surprising nor diminishing the value of this NAFLD model. We did not apply selection for human hepatocytes in the murine liver during feeding experiments, and it is conceivable that steatotic human hepatocytes do not regenerate as efficiently as non-steatotic human hepatocytes in this chimeric mouse model. Although we do not provide direct evidence for this hypothesis, it is well established that liver regeneration is severely reduced in patients with NAFLD,41,42 which seems to translate to regeneration during homeostasis in this NAFLD xenograft model. Further, in the present study we used human hepatocytes from only three donors and human steatosis is likely to depend on patient genotypes. For instance, it has been shown by GWAS that the single variant (rs738409, C>G, I148M) in the patatin-like-phospholipase domain-containing protein 3 (PNPLA3) gene is associated with increased liver fat content.13 This variant has a high prevalence in the Hispanic population and could also be found in 2 of our 3 donors (not shown). However, the third donor had two wild-type alleles in the PNPLA3 gene and developed the same degree of steatosis as the PNPLA3 I148M variants. To demonstrate a difference in steatosis between highly polymorphic human hepatocytes, many more donors are needed, which is outside of the scope of this study. However, as shown here this NAFLD xenograft model offers the possibility to use isogenic controls (same hepatocytes), which can compensate for the high degree of polymorphism in humans.

Another interesting observation was the lack of increase of body weight despite 12 weeks of WD feeding. Although we were unable to detect changes in hepatic markers of energy expenditure that could explain this phenotype, it is possible that the genetic background of mice impacts their susceptibility to diet-induced obesity.44,45 Nonetheless, NAFLD also occurs in lean individuals with a global prevalence ranging from 5 to 26%.46 And non-obese patients with NAFLD share metabolic features with obese patients with NAFLD, including insulin resistance, dyslipidaemia, and metabolic syndrome, and there is little appreciable difference in NAFLD progression between those groups.46,47 Our NAFLD mice are also immunodeficient and are unlikely to develop the inflammatory changes or fibrosis that lead to NASH. In addition, current technology does not allow efficient repopulation of human non-parenchymal cells, which would be necessary for modelling fibrosis. Notwithstanding, our humanised NAFLD mice unire the experimental tractability of the mouse with the translational value of human hepatocytes. Our NAFLD model will be useful for mechanistic studies on the molecular basis of the disease, as well as preclinical testing of experimental therapies, thereby enabling the discernment of cellular processes that are truly relevant to human NAFLD.

Abbreviations
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPBEs, cholesterol biosynthesis pathway enzyme genes; CE, cholesteryl ester; CER, ceramide; CHHs, chimeric human hepatocytes; CMHs, chimeric mouse hepatocytes; CT, confidence transcript; DAG, diacylglycerol; DCER, dihydroceramide; DEG, differentially expressed gene; FA, fatty acid; FAH, fumarylacetoacetate hydrolase; FFA, free fatty acid; GGCT, gamma-glutamyl transpeptidase; hALB, human albumin; HCC, hepatocellular carcinoma; HCER, hexosylceramide; HCT, high confidence transcriptional target; LCR, lactoylceramide; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; MAG, monoacylglycerol; MUFA, monounsaturated fatty acid; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NC, normal chow; NTBC, nitrobenzoxadiazole; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PNPLA3, patatin-like-phospholipase domain-containing protein 3; PUFA, polyunsaturated free FA; SM, sphingomyelin; SREBP, sterol regulatory element-binding protein; TAG, triacylglycerol; TIRF, transgene-free Il2rg–/–/Il2rg–/–; WD, Western-type diet.

Financial support
Supported by the National Heart Lung and Blood Institute (R01 HL134510 to K.D.B. and R01 HL132840 to W.R.L.), National Institute of Diabetes and Digestive and Kidney Disease (R01 DK115461 to K.D.B.; R01 DK056626, R01 DK103466, and R37 DK048872 to D.E.C.; DK097748 to N.J.M.) and the American Heart Association (18POST33990445 and 20CDA5340013 to M.A.-B.). The TEAM programme of the Foundation for Polish Science co-financed by the European Union under the European Regional Development Fund to M.B., and POLONEZ grant from National Science Center (2015/19/P/ZN3/03452) and UE Horizon 2020 (MSCA 665778) to M.B.

Conflicts of interest
The authors declare no personal or financial conflicts of interest.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions
Designed the experiments: K.D.B., B.B.C. Primary data analysis: B.B.C., M.A.-B. Performed in vivo experiments: B.B.C., M.A.-B. Tissue isolation and preparations: X.L. Assisted with hepatocyte handling and procurement: A.M.D., N.T.N.G., K.D.B., B.B.C. Primary data analysis: W.R.L., D.D.M., D.E.C. Read and approved the final manuscript: all authors.

Data availability statement
RNA-Seq data are available from the European Nucleotide Archive, ENA accession code (PRJEB35014).

Acknowledgements
We thank Vicky Brandt for critical comments on the manuscript.

Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhepr.2021.100281.

References
[1] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
[2] Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver. Compr Physiol 2017;8:1–8.
[3] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci 2019;76:99–128.
[4] Font-Burgada J, Sun B, Karin M. Obesity and cancer: the oil that feeds the flame. Cell Metab 2016;23:48–62.
[5] Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8:35–44.

JHEP Reports 2021 vol. 3 | 100281
9
[6] Han J, Dzierlenga AL, Liu Z, Billheimer DD, Torabzadeh E, Lake AD, et al. Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model. Obesity (Silver Spring) 2017;25:1069–1076.

[7] Barzi M, Pankow JP, Zorman B, Liu X, Legras X, Yang D, et al. A novel humanized mouse lacking murine PPARγ oxidoreductase for studying human drug metabolism. Nat Commun 2017;8:39.

[8] Bissig-Choisat B, Wang L, Legras X, Saha PK, Chen L, Bell P, et al. Development and rescue of human familial hypercholesterolemia in a xenograft mouse model. Nat Commun 2015;6:7339.

[9] Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010;120:924–930.

[10] Hatori M, Volimmers C, Zarrinpar A, DiTacchio L, Bushong EA, Gill S, et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab 2012;15:848–860.

[11] Ochsner SA, Abraham D, Martin K, Ding W, McOwitt A, Kankanamge W, et al. The Signaling Pathways Project, an integrated ‘omics knowledgebase for mammalian cellular signaling pathways. Sci Data 2019;6:252.

[12] Mi H, Huang X, Muruganujan A, Tang H, Mills K, Kang D, et al. PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res 2017;45:D183–D189.

[13] Fabregat A, Sidirooulos K, Garpati P, Gillespie M, Hausmann K, Haw R, et al. The reactome pathway knowledgebase. Nucleic Acids Res 2016;44:D481–D487.

[14] Ochsner SA, Fililch RT, McKenna NJ. Consensus transcriptional regulatory networks of coronavirus-infected human cells. Sci Data 2020;7:314.

[15] Bissig KD, Le TT, Woods NB, Verma IM. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci USA 2007;104:214–226.

[16] Han J, Dzierlenga AL, Lu Z, Billheimer DD, Torabzadeh E, Lake AD, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012;15:665–674.

[17] Gouveia O, Cocksell S, Tinakos D, Queen R, Younes R, Vacca M, et al. Translomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med 2020;12:eaba4448.

[18] Namjoo B, Lingren T, Huang Y, Parameswaran S, Cobb BL, Stanaway JR, et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med 2019;17:135.

[19] Horton JD, Goldstein JL, Brown MS. SREBP: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125–1131.

[20] Moslehi A, Hamidi-Zad Z. Role of SREBP in liver diseases: a mini-review. J Transl Med 2018;6:332–338.

[21] Bartz F, Kern L, Erz D, Zhu M, Gilbert D, Meinhof T, et al. Identification of cholesterol-regulating genes by targeted RNAi screening. Cell Metab 2009;10:63–75.

[22] Mao Z, Feng M, Li Z, Zhou M, Xu L, Pan K, et al. ETV5 regulates hepatic fatty acid metabolism through PPAR signaling pathway. Diabetes 2021;70:214–226.

[23] Futema M, Plagnol V, Li K, Whittall RA, Neil HA, Seed M, et al. Whole exome sequencing of familial hypercholesterolemia patients negative for LDLR/ABO/PCSK9 mutations. J Med Genet 2014;51:537–544.

[24] Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n – 6 in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004;106:635–643.

[25] Elizondo A, Araya J, Rodrigo R, Ponijakich J, Cesendes A, Maluenda F, et al. Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity (Silver Spring) 2007;15:24–31.

[26] Araya J, Rodrigo R, Pettinelli P, Araya AV, Videla J, Videla LA. Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. Obesity (Silver Spring) 2010;18:1460–1463.

[27] Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, et al. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 2000;1492:1080–1086.

[28] Liu D, Wong CC, Fu L, Chen H, Zhao I, Li C, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med 2018;10:eaap9840.

[29] Dutkowski P, Linecker M, DeOliveira ML, Mullhaupt B, Clavien PA. Challenges in liver transplantation and strategies to improve outcomes. Gastroenterology 2015;148:307–323.

[30] McCormack L, Petrovsky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007;245:923–930.

[31] Romeo S, Kozlitina J, Xing C, Pertsovskis A, Cox D, Penacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461–1465.

[32] Geisler CE, Hepler C, Higgins MR, Renquist BJ. Hepatic adaptations to maintain metabolic homeostasis in response to fasting and refeeding in mice. Nutr Metab 2016;13:62.

[33] Andrikopoulos S, Massa CM, Aston-Mourney K, Funkat A, Fam BC, Hull RL, et al. Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129/2tf) on insulin secretory function in response to a high fat diet. J Endocrinol 2005;187:45–53.

[34] Wang AY, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clin Nutr 2019;38:975–981.

[35] Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol 2017;15:474–485.

[36] Teufel A, Izuel T, Erhart W, Brosch M, Wang XY, Kim YO, et al. Comparison of Gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. Gastroenterology 2016;151:513–525.
A human liver chimeric mouse model for non-alcoholic fatty liver disease

Authors
Beatrice Bissig-Choisat, Michele Alves-Bezerra, Barry Zorman, Scott A. Ochsner, Mercedes Barzi, Xavier Legras, Diane Yang, Malgorzata Borowiak, Adam M. Dean, Robert B. York, N. Thao N. Galvan, John Goss, William R. Lagor, David D. Moore, David E. Cohen, Neil J. McKenna, Pavel Sumazin, Karl-Dimiter Bissig

Correspondence
karldimiter.bissig@duke.edu (K.-D. Bissig).

Graphical abstract

Highlights

- Human liver chimeric mice fed a western diet develop NAFLD.
- Within the same chimeric liver, human hepatocytes developed pronounced steatosis while murine hepatocytes remained normal.
- Unbiased metabolomics and lipidomics of fatty humanised mouse livers revealed signatures of clinical NAFLD.
- Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes.
- This humanised NAFLD model is a physiologically relevant, experimentally tractable model for the study of steatosis.

Lay summary
Fatty liver disease is an emerging health problem, and as there are no good experimental animal models, our understanding of the condition is poor. We here describe a novel humanised mouse system and compare it with clinical data. The results reveal that the human cells in the mouse liver develop fatty liver disease upon a Western-style fatty diet, whereas the mouse cells appear normal. The molecular signature (expression profiles) of the human cells are distinct from the mouse cells and metabolic analysis of the humanised livers mimic the ones observed in humans with fatty liver. This novel humanised mouse system can be used to study human fatty liver disease.

https://doi.org/10.1016/j.jhepr.2021.100281
A human liver chimeric mouse model for non-alcoholic fatty liver disease

Beatrice Bissig-Choisat,1,† Michele Alves-Bezerra,2,† Barry Zorman,3 Scott A. Ochsner,4 Mercedes Barzi,1 Xavier Legras,1 Diane Yang,4 Malgorzata Borowiak,1,5 Adam M. Dean,4 Robert B. York,4 N. Thao N. Galvan,6 John Goss,1 William R. Lagor,2 David D. Moore,4 David E. Cohen,1 Neil J. McKenna,4 Pavel Sumazin,1 Karl-Dimiter Bissig4,8,9,10,11,*

1Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, USA; 2Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, USA; 3Texas Children’s Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; 4Institute for Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University, Poznan, Poland; 5Department of Surgery, Texas Children’s Hospital, Houston, TX, USA; 6Joan & Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA; 7Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center, Duke University, Durham, NC, USA; 8Division of Gastroenterology, Department of Medicine, Duke University, Durham, NC, USA; 9Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA; 10Duke Cancer Institute, Duke University, Durham, NC, USA

JHEP Reports 2021. https://doi.org/10.1016/j.jhepr.2021.100281

Background & Aims: The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and animal studies, our understanding of NAFLD pathogenesis remains limited. To better study the molecular changes driving the condition we aimed to generate a humanised NAFLD mouse model.

Methods: We generated TIRF (transgene-free Il2rg−/−/Rag2−/−/Fah−/−) mice, populated their livers with human hepatocytes, and fed them a Western-type diet for 12 weeks.

Results: Within the same chimeric liver, human hepatocytes developed pronounced steatosis whereas murine hepatocytes remained normal. Unbiased metabolomics and lipidomics revealed signatures of clinical NAFLD. Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes, demonstrating stark species differences in liver function. Regulatory network analysis indicated close agreement between our model and clinical NAFLD with respect to transcriptional control of cholesterol biosynthesis.

Conclusions: These NAFLD xenograft mice reveal an unexpected degree of evolutionary divergence in food metabolism and offer a physiologically relevant, experimentally tractable model for studying the pathogenic changes invoked by steatosis.

Lay summary: Fatty liver disease is an emerging health problem, and as there are no good experimental animal models, our understanding of the condition is poor. We here describe a novel humanised mouse system and compare it with clinical data. The results reveal that the human cells in the mouse liver develop fatty liver disease upon a Western-style fatty diet, whereas the mouse cells appear normal. The molecular signature (expression profiles) of the human cells are distinct from the mouse cells and metabolic analysis of the humanised livers mimic the ones observed in humans with fatty liver. This novel humanised mouse system can be used to study human fatty liver disease.

© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

The global spread of high-fat, high-sugar diets and sedentary lifestyles carries with it a sharp rise in non-alcoholic fatty liver disease (NAFLD).1 Hepatic steatosis is considered problematic because it leads to inflammation and fibrosis, creating the more serious condition known as non-alcoholic steatohepatitis (NASH).2,3 NASH in turn triggers compensatory cell proliferation, increasing the risk of hepatocellular carcinoma (HCC), which has become the second leading cause of cancer deaths.4 Given that steatosis seems to drive pathogenesis in all these major diseases, there is a pressing need to understand how it changes liver function.

NAFLD has been extremely difficult to study in either human patients or mice. Although transcriptomic, lipidomic, and metabolic profiling studies of human livers are numerous, clinical approaches are generally retrospective and human participants are not experimentally tractable. Studies using murine models present different limitations: genetic models of NAFLD based on single-gene alterations, such as the ob/ob or db/db obese mouse strains, may not accurately reflect the typically
polygenic human situation. Dietary models gain weight, develop steatosis, and become insulin-resistant, but exhibit much less liver injury than human NASH patients, suggesting fundamental differences in rodent and human livers. Indeed, metabolic profiling of rats fed a methionine-choline-deficient diet—which inhibits fatty acid oxidation, thereby leading to NASH—identified species differences in bile acid, insulin, and leptin levels, limiting this model’s utility for studies of biomarkers or disease progression.

Having recently developed human liver chimeric mice to study human drug metabolism, we took a similar approach here to study NAFLD. We demonstrate that humanised TIRF (tran-gene-free, I2rg+/−, Rag2+/−, Fah+/−) mice develop NAFLD when fed a Western-type high fat/high sucrose diet (WD). Metabolic and histological changes of human hepatocytes in xenograft mice resemble those found in human NAFLD, whereas the molecular signatures of the human and murine hepatocytes within the same chimeric livers differ greatly. This chimeric mouse model therefore offers an ideal platform for studying the response of human hepatocytes to diet-induced NAFLD.

**Materials and methods**

**Animals and diets**

The TIRF strain was generated by CRISPR/Cas9 deletion of the 3 genes in mouse zygotes as we described previously and crossing out the P450 oxidoreductase (Por) gene from the PIRF (Por−/−, I2rg−/−, Rag2−/−, Fah−/−) strain.

Human hepatocytes (1 × 10⁶ per mouse) were transplanted by splenic injection into the livers of 3-week-old male and female TIRF mice maintained on the drug nitisinone (NTBC) from the splenic injection into the livers of 3-week-old male and female TIRF mice. Immediately after transplantation, we applied selection pressure toward transplanted chimeric human hepatocytes (CHHs) by step-wise reduction and withdrawal of NTBC. Human albumin (hALB) levels (ELISA, Bethyl Laboratories, Inc., Montgomery, TX, USA) in the plasma of transplanted mice was measured to gauge the extent of chimerism. Only mice with >70% human liver chimerism were used and put on NTBC (no tyrosinemic stress of murine hepatocytes) for the remainder of the study.

Humanised mice were fed normal chow (NC) (2019 Teklad global 19% protein extruded rodent diet, Envigo, Madison, Wisconsin USA) or WD (D12079B, RD Western Diet, Research Diets, New Brunswick, New Jersey, USA) for 12 weeks. Mice were euthanised after a 6-h fast and plasma was collected. Livers were then harvested and snap-frozen in liquid nitrogen and stored at -80°C. All animal experiments were approved by the Institutional Animal Care and Use Committee. Animals received humane care according to the criteria outlined in the NIH Guide for the Care and Use of Laboratory Animals.

**Metabolomic and lipidomic analyses**

Sample preparation and analysis for global metabolomics was carried out at Metabolon Inc. (Durham, NC, USA) as described by Hatori et al., with modifications (see Supplementary Methods).

Lipids for untargeted lipidomics were extracted from snap-frozen liver samples at Metabolon Inc. using dichloromethane and methanol in the presence of deuterated internal standards. Details for extraction and analysis can be found in the Supplementary Methods.

**RNA-sequencing, data processing, and NAFLD consensome analysis**

Whole-transcriptome RNA-sequencing (RNA-Seq) was performed using total RNA isolated using a Purelink RNA mini kit (Invitrogen PureLink RNA Mini Kit, ThermoFisher Scientific, USA). RNA-seq read pairs were aligned to a combined human (hg38) and murine (mm10) genome using STAR version 2.7.1a. RNA-Seq data is available from European Nucleotide Archive, ENA accession code (PRJEB35014). See Supplementary Methods for details of library generation and gene expression quantification.

To generate the human NAFLD consensome, we first retrieved a total of 9 Gene Expression Omnibus clinical NAFLD or NASH case-control transcriptomics datasets (Table S6, section 3) (see Supplementary Methods). Differential expression values were committed to the consensome analysis pipeline as previously described. Panther and Reactome pathway analysis was used to evaluate enrichment of biological processes in NAFLD consensome confidence transcripts (CTs) or H:M>1.2 genes. Node high confidence transcriptional target (HCT) intersection analysis was performed as previously described.

Additional methods are described in the Supplementary Methods.

**Results**

**Human liver chimeric mice develop steatosis after 12 weeks on a WD**

To evaluate the susceptibility of xenograft mice to diet-induced NAFLD, we developed the TIRF strain. In contrast to previous Fah−/−/Rag2+/−/I2rg−/− mice, this strain has no neomycin-resistance cassettes that could confound results in several ways. The neomycin phosphotransferase gene can influence the metabolism of transgenic mice; the transgene can alter gene expression and has been shown to increase expression of both c-myc and various liver genes; and it was shown to reduce fructose 2,6-bisphosphate and lactate in fibroblasts.

Three-week-old male and female TIRF mice were humanised by splenic injection of human hepatocytes from 1 of 3 different healthy human donors (Fig. 1A). Three to 4 months after transplantation, human chimerism was assessed by measurement of hALB in the murine plasma and only mice with >70% human hepatocytes were used in subsequent studies. Mice bearing human hepatocytes were randomised and fed either WD or NC for 12 weeks (Fig. 1A). To mimic low mitotic index of the human liver, we removed selection pressure for human hepatocytes in humanised mice (see Methods for details).

Relative to NC, WD induced no significant change in body or liver weight (Fig. 1B and C), blood chemistries (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transpeptidase; Fig. 1D) or fasting levels of plasma triacylglycerols or glucose over the 12-week period. Plasma cholesterol, however, increased 70% (Fig. 1E). This is consistent with observations from patients with NAFLD, where intrahepatic fat accumulation occurs before the development of obesity or abnormalities in standard liver function tests. As no selection pressure for human hepatocytes was applied, we compared hALB levels before and after 12 weeks on WD, respectively, with NC. There was no significant decrease on NC, but WD decreased the human albumin levels from an average of 4.8 mg/ml to 2.2 mg/ml (Fig. 51).
We next examined histological changes in livers of humanised mice in response to 12 weeks of WD. H&E staining identified pronounced macrovesicular steatosis with microvesicular components (Fig. 2A and B). Immunostaining for fumarylacetoacetate hydrolase (FAH) confirmed that steatosis was confined to human hepatocytes, repopulating across the whole liver acinus (Fig. 2A and C). Oil-Red-O staining further confirmed lipid accumulation (Fig. S2). Staining for connective tissue (Trichrome Masson) and the liver-resident macrophages (Kupffer cells, F4/80), did not show appreciable differences between murine and human regions of the chimeric livers (Fig. 2A).

Collectively, these findings indicate that humanised TIRF mice develop human hepatocyte-specific steatosis after 12 weeks of WD, replicating early clinical NAFLD.

**Distinct hepatic metabolite profiles between NAFLD and control xenograft mice**

Because livers of patients with NAFLD undergo profound metabolic changes in comparison with livers of patients without steatosis, we searched for similar effects in WD-fed humanised mice. Using global metabolomic profiling, we found that among 565 identified metabolites, 48 were significantly increased and 59 were significantly decreased in livers of NAFLD chimeric mice compared with controls (Table 1 and S1). Among metabolites with the largest increases were cholesterol, 4-cholen-3-one (an intermediate in the synthesis of bile acids) and the antioxidant α-tocopherol (Table 1 and S1). Metabolic pathway enrichment analysis showed WD-induced increases in hepatic concentrations of long-chain and branched free fatty acids (FFAs), intermediates of endocannabinoid, sphingosine, and acylcholine metabolism (Fig. 3A and C). In contrast, we observed WD-induced decreases in levels of metabolites associated with xenobiotic metabolism, vitamin A, and benzoate (Table 1 and Fig. 3B and C), which have been previously found to be reduced in patients with NAFLD. Similarly, WD decreased levels of polyunsaturated free fatty acid (PUFA) species (Fig. 3B and C) and dihydroxy fatty acid (FA) lipid peroxide markers (Table 1 and S1). Conversely, the WD induced increases in levels of docosahexaenoate and mead acid (Table 1).

**Humanised mouse livers have lipid profiles similar to those of patients with NAFLD**

Accumulating evidence suggests that NAFLD progression is associated with changes in hepatic lipid species composition and concentration. The observation that levels of FFA species were altered in livers of WD-fed humanised mice prompted us to evaluate whether this would be reflected in changes in the overall hepatic lipid profile. Although most studies have used targeted analysis, we used untargeted lipidomics and found increased steady-state concentrations of cholesteryl esters (CEs), diacylglycerols (DAGs), triacylglycerols (TAGs), ceramides (CERs), and lactosylceramides (LCERs) in livers of WD-fed chimeric mice in comparison with NC-fed counterparts (Fig. 4A and Table S2).

We next examined the influence of the WD in the composition of FAs that are esterified to complex lipids in livers of xenograft mice. The composition of FFAs as well as FAs in DAG, TAG, and lysophosphatidylethanolamine exhibited increased odd, saturated, and monounsaturated fatty acid (MUFA) species, along with decreased PUFAs (Fig. 4B), resembling livers of patients with NAFLD. In the chimeric mice, hepatic steatosis
MUFAs, with an overall decrease in saturated and PUFA species (Table S2). Sphingolipids reflected a preference for the esterification of medium- to long-chain saturated FAs and MUFAs, along with decreased esterification of very long-chain saturated FAs (Fig. 4B).

Mouse and human hepatocytes of NAFLD xenograft mice exhibit different transcriptional profiles

To determine whether changes in hepatic metabolites and lipids could be attributable to altered transcriptional profiles in the NAFLD model, we performed a transcriptional analysis of CHHs in NC- and WD-fed chimeric mice. We identified a total of 681 differentially expressed genes (DEGs) when comparing WD-fed with NC-fed chimeric mice (Fig. 5A and B, Table S3 and S4). Pathway enrichment analysis revealed that upregulated genes (52 genes; 7.6% of total DEGs) were predominantly associated with lipid metabolism and amino acid catabolism, whereas downregulated genes (629 genes; 92.4% of total DEGs) were primarily related to cholesterol metabolism, including cholesterol biosynthesis and sterol regulatory element-binding proteins (SREBP)-regulated genes (Fig. S3, Table S3 and S4).

Next, we analysed the transcriptional profile of chimeric murine hepatocytes (CMHs) in the same groups of chimeric mice. Upon WD feeding, mouse hepatocytes exhibited a total of 1,196 DEGs in comparison to NC-fed controls (Fig. 5C, Table S3 and S5). Notably, mouse DEGs showed little overlap with human DEGs. Among 87 upregulated mouse genes (7.3% of total DEGs), only 2 were also upregulated in human hepatocytes (Arsb/ARSB and Fatp2/SLC27A2) (Fig. 5D). Similarly, 1,109 mouse orthologues were shown to be downregulated (92.7% of total DEGs), from which only 92 genes were also identified among downregulated human orthologues (Fig. 5D). These findings indicate that, in the setting of hepatic steatosis, the mouse hepatocyte transcriptional signature markedly differs from the human counterparts.

Alignment of cholesterol biosynthesis transcriptional networks between xenograft human hepatocytes and clinical NAFLD

Given the abundant evidence connecting cholesterol metabolism to NAFLD,28 we next explored transcriptional mechanisms that might contribute to the marked rise in plasma and hepatic cholesterol levels observed in chimeric mice upon WD-feeding (Fig. 1E and Table S1). We generated a list of transcripts that were differentially expressed ($P < 0.05$) in response to WD in both CHHs and CMHs, and had relative CHH:CMH expression levels that exceeded 20% (H:M>1.2; Table S6, section 1). Pathway analyses of this gene set reflected significant enrichment of genes mapped to cholesterol biosynthesis and SREBP-regulated gene expression (Fig. 6A). Closer inspection of the H:M>1.2 transcripts indicated that 6 represented de novo cholesterol biosynthesis pathway enzyme genes (CBPEGs; Fig. 6B and Table S6, sections 1 and 2). Notable among these were squalene epoxidase (SQLE), which catalyses the rate-limiting conversion of squalene to 2,3-oxidosqualene, and dehydrocholesterol reductase 7 (DHCR7), the terminal enzyme in the Kandutsch-Russell pathway for cholesterol synthesis. Although CBPEGs were repressed in both CMHs and CHHs in response to WD-feeding, this downregulation was much less efficient in CHHs, such that CBPEGs were expressed at levels up to 2.4-fold higher in CHHs relative to CMHs (Fig. 6B and Table S6, section 2).
We next evaluated the extent to which elevated expression levels of CBPEGs in the CHHs relative to the CMHs reflected clinical NAFLD. Using our previously-described consensome algorithm, we generated a clinical NAFLD transcriptomic consensome (Fig. 6C), which ranks ~18,100 human genes according to the frequency with which they are upregulated or downregulated across 22 independent published clinical NAFLD case-control transcriptomic datasets (Table S6, sections 2 and 3).
Validating the NAFLD consensome, a 25-gene signature recently published by Govaere et al. \[^{29}\] that predicts clinical NAFLD severity was robustly enriched among mean FC ≥ 1.25 clinical NAFLD CTs (Q = 0.05) in the consensome (GOVAERE: OR = 12.3, \( p \leq 2 \times 10^{-9} \); Fig. 6C and Table S6, section 2). Confirming the xenograft mouse as an accurate model of clinical NAFLD, we identified a very strong enrichment of the 6 CBPEGs (Fig. 6B) among the same set of clinical NAFLD CTs (CBPEGs: OR = 27, \( p = 4 \times 10^{-6} \); Fig. 6C). Taken together, these data demonstrate a robust convergence between the elevated expression of CBPEGs in clinical NAFLD and in steatotic CHHS in the chimeric mice.

We next wished to gain insight into the extent to which transcriptional drivers of the xenograft model CBPEGs aligned with those implicated in human clinical NAFLD. To investigate this, we performed node HCT intersection analysis, which generates statistical measures of intersections between a given set of genes and HCTs for cellular signalling pathway nodes. \[^{14}\] For HCT intersection analysis, we computed intersections between the CBPEGs and NAFLD consensome case:control FC ≥ 1.2 CTS (NAFLD UP) and a library of signalling pathway node HCTs (Fig. 6D and Table S6, section 4). We benchmarked this analysis against a study that identified PPARG, FJ1, SPI1, and CEBPA as liver transcriptional drivers of a set of genes that had significant genome-wide association studies (GWAS) associations with NAFLD. Validating our HCT intersection analysis, 3 of these 4 nodes had NAFLD UP intersections of Q < 1e-3 (NAMJOU: OR = 55.44, \( p = 7.6e^{-6} \); Fig. 6D and Table S6, section 4). We identified 4 nodes that had Q < 0.05 intersections with the CBPEGs: SREBF1 (Q = 8e-10), SREBF2 (Q = 1e-4), ETV5 (Q = 8e-3) and RBM25 (Q = 5e-3). Again, reflecting close agreement between our model and clinical NAFLD, all 4 also had Q < 0.05 intersections with NAFLD UP gene set (OR = 16.3, \( p = 1.2e^{-5} \), hypergeometric test; Fig. 6D and Table S6, section 4). SREBF1 and SREBF2 are both connected by abundant evidence to cholesterol biosynthesis \[^{11}\] and NAFLD pathogenesis. \[^{32}\] ETV5 is a transcriptional regulator of hepatic cholesterol transport and biosynthesis \[^{23}\] recently implicated in hepatic steatosis. \[^{24}\] Finally, a variant of RBM25 has been previously associated with familial hypercholesterolaemia. \[^{25}\] Collectively, our reduced-bias, consensus-driven approach reflects close convergence between cholesterol biosynthesis transcriptional regulatory networks in our xenograft model and those driving clinical NAFLD.

**Discussion**

Our goal in this study was to establish and characterise a mouse model that faithfully replicated the pathophysiology of human NAFLD. Our humanised TIRF mice recapitulate histological, metabolic and transcriptional features of human NAFLD after 12 weeks on WD, with steatosis being confined in large to the human hepatocytes.

There were several similarities between lipid profiles in the NAFLD xenograft mice and patients with NAFLD. Free cholesterol and triacylglycerol lipid classes are increased both in livers of patients with NAFLD \[^{21,26}\] and NAFLD xenograft mice, as are hepatic concentrations of cholesteryl esters, which supports the role of these lipids in the pathogenesis of NAFLD. Multiple

---

**Table 1. Top differentially regulated metabolites in NAFLD xenograft mice.** *Humanised mice on WD (NAFLD) compared with humanised mice on normal chow (control). NAFLD, non-alcoholic fatty liver disease; WD, Western-type diet.

| Metabolite               | Pathway                          | \( p \) value | Fold change (NAFLD vs. control) |
|-------------------------|----------------------------------|---------------|---------------------------------|
| **Increased**            |                                  |               |                                 |
| Docosatrienoate (22:3n6) | Polyunsaturated fatty acid (n3 and n6) | 1.12E-02      | 12.50                           |
| Mead acid (20:3n9)       | Polyunsaturated fatty acid (n3 and n6) | 4.56E-04      | 11.95                           |
| (14 or 15)-methylpalmitate (a17:0 or i17:0) | Fatty acid, Branched | 3.89E-03      | 10.10                           |
| 1-octadecenoate (12:1)  | Long chain fatty acid            | 8.93E-03      | 9.18                            |
| 10-heptadecenoate (17:1n7) | Long chain fatty acid            | 1.46E-03      | 5.44                            |
| 10-nondecanoate (19:1n9) | Long chain fatty acid            | 3.41E-06      | 4.74                            |
| Myristoleate (14:1n5)    | Long chain fatty acid            | 1.58E-02      | 4.24                            |
| N-oleyltaurine           | Endocannabinoid                  | 2.99E-02      | 3.97                            |
| Pentadecanoate (15:0)    | Long chain fatty acid            | 1.71E-02      | 3.76                            |
| Eicosanoate (20:1)       | Long chain fatty acid            | 1.64E-04      | 3.53                            |
| Oleylcholine             | Fatty acid metabolism            | 2.68E-02      | 3.26                            |
| (16 or 17)-methylstearate (a19:0 or i19:0) | Fatty acid, branched            | 4.40E-06      | 3.09                            |
| Heptadecaphosphosine (17:1) | Sphingosines                    | 1.29E-03      | 3.02                            |
| Palmitoleate (16:1n7)    | Long chain fatty acid            | 9.18E-04      | 2.81                            |
| 1-octolyl-GPS (18:1)     | Lysophospholipid                 | 1.94E-02      | 2.54                            |
| **Decreased**            |                                  |               |                                 |
| Homostachydrine          | Food component/Plant             | 3.64E-04      | 0.01                            |
| Stachydrine              | Food component/Plant             | 3.99E-04      | 0.02                            |
| Docosatrienoate (22:3n3) | Polyunsaturated fatty acid (n3 and n6) | 1.46E-05      | 0.02                            |
| Trigonelline (N-methylnicotinate) | Nicotinamide metabolism      | 1.30E-03      | 0.03                            |
| Histidine betaine (hercynine) | Food component/Plant          | 4.89E-05      | 0.08                            |
| 4-guanidinobutanoate     | Guanidino and acetamido metabolism | 9.09E-03      | 0.10                            |
| N,N,N-trimethyl-5-anovalerat | Lysine metabolism             | 8.95E-03      | 0.15                            |
| Cis-4-decenolate (10:1n6) | Medium chain fatty acid         | 9.88E-06      | 0.17                            |
| Carotene diol (1)        | Vitamin A metabolism            | 3.22E-03      | 0.21                            |
| Ergothioneine            | Food component/plant            | 7.38E-05      | 0.21                            |
| 13-HODE + 9-HODE         | Fatty acid, monohydroxy         | 1.65E-02      | 0.21                            |
| 3-sulfo-L-alanine        | Methionine, cysteine, S-adenosylmethionine | 1.44E-02      | 0.22                            |
| P-c resol glucuronide    | Tyrosine metabolism             | 2.59E-03      | 0.24                            |
| 4-hydroxy-nonenal-glutathione | Glutathione metabolism     | 6.13E-03      | 0.25                            |
| Gamma-tocopherol/beta-tocopherol | Tocopherol metabolism   | 5.01E-04      | 0.27                            |
studies have suggested that PUFA depletion also contributes to the pathogenesis of human NAFLD. Obese NAFLD patients exhibit marked decreases in hepatic concentrations of n-3 PUFAs, and two mechanisms have been proposed to explain this observation: (i) an increased utilisation of n-3 PUFAs owing to the high oxidative status, and (ii) a reduced capacity for desaturation of α-linoleic acid (18:3n-3; a precursor of n-3 PUFAs) owing to decreases in hepatic activities of D-5 and D-6 desaturases. In line with this, livers of chimeric mice showed lower concentrations of PUFAs along with a trend towards downregulated expression of PPARα and SREBP1c, thereby promoting FA oxidation at the expense of lipogenesis in chimeric livers. Illustrating this, we identified 6 CPBEGs that were highly repressed in response to WD in CMHs, but to a lesser extent in CHHs. Using a reduced-bias consensome meta-analysis of published NAFLD transcriptomic datasets, we demonstrated that the elevated expression of CBPEGs in CHHs relative to CMHs closely reflected the relative expression levels of their human orthologs between clinical NAFLD and normal livers. The gene with the highest CHH:CMH ratio (2.4), and the highest ranked CBPEG in the NAFLD consensome (23rd of 18,162 genes) was SQLE, whose expression has been connected to the pathogenesis of hepatic steatosis and its subsequent progression to hepatocellular carcinoma. Indeed, the identification of squalene oxidase as a major mediator of increased hepatic biosynthesis of cholesteryl esters represents a plausible explanation for the elevated levels of

Fig 4. Altered lipid profile in livers of NAFLD xenograft mice. Global lipid profiles were determined in livers of 12-week WD or NC chimeric mice (n = 8 per group). (A) Hepatic levels of lipids. *p < 0.05, **p < 0.01, and ***p < 0.001 using Welch’s t-test. (B) Hepatic fatty acyl composition (relative to NC-fed humanised mice). Grey boxes, data not available. CE, cholesteryl ester; CER, ceramide; DAG, diacylglycerol; DCER, dihydroceramide; FFA, free fatty acid; HCER, hexosylceramide; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; MAG, monoacylglycerol; NAFLD, non-alcoholic fatty liver disease; NC, normal chow; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; TAG, triacylglycerol; WD, Western-type diet.
Fig 5. Divergent transcriptional responses to WD between CHHs and CMHs in NAFLD xenograft mice. Transcriptomic analysis of human (A and B) and mouse (C and D) hepatocytes was performed in livers of 12 week WD or NC chimeric mice (n = 8 per group). Upregulated genes in the WD-fed mice relative to the NC group are shown in red, downregulated genes are in blue. (D) Groupwise comparison of differentially expressed mouse and human genes (WD vs. NC). CHHs, chimeric human hepatocytes; CMHs, chimeric mouse hepatocytes; NC, normal chow; NAFLD, non-alcoholic fatty liver disease; WD, Western-type diet.

Fig 6. Distinct human and mouse cholesterol biosynthesis enzyme expression profiles in chimeric livers recapitulate clinical NAFLD. (A) Enrichment of SREBP1-cholesterol biosynthesis transcriptional pathways connects chimeric human hepatocytes (CHHs) and clinical NAFLD. (B) H:M >1.2 genes encode enzymes in the de novo cholesterol biosynthesis pathway. Enzyme names are shown in (D). Red numerals refer to CHH:CMH relative expression ratios. (C) The human NAFLD transcriptomic consensome ranks 18,162 genes based on their discovery rates across 20 independent, publicly archived clinical NAFLD case:control transcriptomic datasets. Hypergeometric test statistics for over-representation of the 25-gene NAFLD severity signature (GOVAERE) and CPBEGs among NAFLD CTs (mean case:control FC >1.25) are indicated. Q, FDR-corrected consensome p-value. (D) Node HCT intersection analysis of CPBEGs and FC >1.2 Q <0.05 clinical NAFLD consensome genes. NAFLD UP INT Q<0.05: nodes with significant (Q <0.05) intersections with NAFLD consensome CTs with mean case:control FC>1.2. CPBEGs INT Q <0.05: nodes with significant (Q <0.05) intersections with CPBEGs. Full data are in Table S6, section 4. CBPEG, cholesterol biosynthesis pathway enzyme genes; FC, fold change; FDR, false discovery rate; HCT, high confidence transcriptional target; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; SREBP1, sterol regulatory element-binding protein 1.
these lipid species in livers of WD-fed chimeric mice. Finally, we identified robust evidence for convergence between transcriptional drivers of CBPEG expression and those regulating expression of genes consistently induced in clinical NAFLD.

In addition to its strengths, our NAFLD xenograft model has some limitations. Human albumin levels reveal a slight but significant decrease in humanisation after 12 weeks of WD feeding. Although this might constitute an experimental limitation particularly if animals do not have a high human liver chimerism, this observation is neither surprising nor diminishing the value of this NAFLD model. We did not apply selection for human hepatocytes in the murine liver during feeding experiments, and it is conceivable that steatotic human hepatocytes do not regenerate as efficiently as non-steatotic human hepatocytes in this chimeric mouse model. Although we do not provide direct evidence for this hypothesis, it is well established that liver regeneration is severely reduced in patients with NAFLD,41,42 which seems to translate to regeneration during homeostasis in this NAFLD xenograft model. Further, in the present study we used human hepatocytes from only three donors and human steatosis is likely to depend on patient genotypes. For instance, it has been shown by GWAS that the single variant (rs738409, C>G, 1148M) in the patatin-like-phospholipase domain-containing protein 3 (PNPLA3) gene is associated with increased liver fat content.43 This variant has a high prevalence in the Hispanic population and could also be found in 2 of our 3 donors (not shown). However, the third donor had two wild-type alleles in the PNPLA3 gene and developed the same degree of steatosis as the PNPLA3 I148M variants. To demonstrate a difference in steatosis between highly polymorphic human hepatocytes, many more donors are needed, which is outside of the scope of this study. However, as shown here this NAFLD xenograft model offers the possibility to use isogenic controls (same hepatocytes), which can compensate for the high degree of polymorphism in humans.

Another interesting observation was the lack of increase of body weight despite 12 weeks of WD feeding. Although we were unable to detect changes in hepatic markers of energy expenditure that could explain this phenotype, it is possible that the genetic background of mice impacts their susceptibility to diet-induced obesity.44,45 Nonetheless, NAFLD also occurs in lean individuals with a global prevalence ranging from 5 to 26%,46 and non-obese patients with NAFLD share metabolic features with obese patients with NAFLD, including insulin resistance, dyslipidaemia, and metabolic syndrome, and there is little appreciable difference in NAFLD progression between those groups.46,47 Our NAFLD mice are also immunodeficient and are unlikely to develop the inflammatory changes or fibrosis that lead to NASH. In addition, current technology does not allow efficient repopulation of human non-parenchymal cells, which would be necessary for modelling fibrosis. Notwithstanding, our humanised NAFLD mice unite the experimental tractability of the mouse with the translational value of human hepatocytes. Our NAFLD model will be useful for mechanistic studies on the molecular basis of the disease, as well as preclinical testing of experimental therapies, thereby enabling the discernment of cellular processes that are truly relevant to human NAFLD.

Abbreviations

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBPEGs, cholesterol biosynthesis pathway enzyme genes; CE, cholesteryl ester; CER, ceramide; CHHs, chimeric human hepatocytes; CMHs, chimeric mouse hepatocytes; CT, confidence transcript; DAG, diacylglycerol; DCER, dihydroceramide; DEG, differentially expressed gene; FA, fatty acid; FFA, free fatty acid; GGT, gamma-glutamyl transpeptidase; hALB, human albumin; HCC, hepatocellular carcinoma; HCT, hexosylceramide; HCT, high confidence transcriptional target; LCER, lactosylceramide; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; MAG, monoacylglycerol; MUFA, monounsaturated fatty acid; NASH, non-alcoholic fatty liver disease; NAFLD, non-alcoholic steatosis; NASH, non-alcoholic steatohepatitis; NC, normal chow; NTCB, nitrosamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PNPLA3, patatin-like-phospholipase domain-containing protein 3; PUFA, polyunsaturated free FA; SM, sphingomyelin; SREBP, sterol regulatory element-binding protein; TAG, triacylglycerol.

Authors’ contributions

Designed the experiments: K.D.B., B.B.C. Primary data analysis: B.B.C., M.A.-B. Performed in vivo experiments: B.B.C., M.A.-B. Tissue isolation and preparations: X.L. Assisted with hepatocyte handling and procurement: A.M.D., N.T.N.G., W.R.L. Financial support: K.D.B., K.D.B., D.D.M., D.E.C., N.J.M. Read and approved the final manuscript: all authors

Data availability statement

RNA-Seq data are available from the European Nucleotide Archive, ENA accession code (PRJEB35014).

Acknowledgements

We thank Vicky Brandt for critical comments on the manuscript.

Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhepr.2021.100281.

References

[1] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
[2] Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver. Compr Physiol 2017;8:1–8.
[3] Besone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci 2019;76:99–128.
[4] Font-Burgada J, Sun B, Karin M. Obesity and cancer: the oil that feeds the flame. Cell Metab 2016;23:48–62.
[5] Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8:35–44.
[6] Han J, Dzierlenga AL, Lu Z, Billheimer DD, Torabzadeh E, Lake AD, et al. Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model. Obesity (Silver Spring) 2017;25:1068–1076.

[7] Barzi M, Pankowicz FP, Zorman B, Liu X, Legras X, Yang D, et al. A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism. Nat Commun 2017;8:39.

[8] Bissig-Choisat B, Wang L, Legras X, Saha PK, Chen L, Bell P, et al. Development and rescue of human familial hypercholesterolemia in a xenograft mouse model. Nat Commun 2015;6:7739.

[9] Ochsner SA, Abraham D, Martin K, Ding W, McOwiti A, Kankanamge W, et al. The Signaling Pathways Project, an integrated ‘omics knowledgebase for mammalian cellular signaling pathways. Sci Data 2019;6:252.

[10] Mi H, Huang X, Muruganujan A, Tang H, Mills K, Kang D, et al. The reactome pathway knowledgebase. Nucleic Acids Res 2017;45:D183–D189.

[11] Fabregat A, Sidropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, et al. The signaling pathways project, an integrated ‘omics knowledgebase for mammalian cellular signaling pathways. Sci Data 2019;6:252.

[12] Zhao A, Jiang J, Li K, Mi H, Li J, Huang X, et al. PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res 2017;45:D481–D487.

[13] Ochsner SA, Fillich RT, McKenna NJ. Consensus transcriptional regulatory networks of coronavirus-infected human cells. Sci Data 2020;7:314.

[14] Bissig KD, Le TT, Woods NB, Verma IM. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci USA 2007;104:20507–20511.

[15] Olson EN, Arnold HH, Rigby PW, Wold BJ. Know your neighbors: three expansions of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice. Nat Biotechnol 2007;25:903–910.

[16] Olson EN, Arnold HH, Rigby PW, Wold BJ. Know your neighbors: three expansions of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice. Nat Biotechnol 2007;25:903–910.

[17] Wattacheril J, Seeley EH, Angel P, Chen H, Bowen BP, Lanciault C, et al. Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis. Plos One 2011;6:e22775.

[18] Wattacheril J, Seeley EH, Angel P, Chen H, Bowen BP, Lanciulli C, et al. Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis. Plos One 2013;8:e57165.

[19] Luukkonen PK, Zhou Y, Sadevira S, Leivonen M, Arola J, Oresic M, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 2016;64:1167–1175.

[20] Chiappini F, Coilly A, Kadar H, Gual P, Tran A, Desterke C, et al. Metabolism of normal and fibrotic human liver. Hepatology 2017:21–32.

[21] Araya J, Rodrigro R, Videla LA. Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese mice. Obesity (Silver Spring) 2007;15:24–31.

[22] Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012;15:665–674.

[23] Gouvea O, Cockell S, Tinakos D, Queen R, Younes R, Vacc M, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Trans Med 2020;12:eaba4448.

[24] Mosleh A, Hamidi-Zad Z. Role of SREBPs in liver diseases: a mini-review. J Clin Transl Hepatol 2018;6:332–338.

[25] Bartz F, Kern L, Erz D, Zhu M, Gilbert D, Meinhof T, et al. Identification of cholesterol-regulating genes by targeted RNAseq screening. Cell Metab 2009;10:63–75.

[26] Hao Z, Feng M, Li Z, Zhou M, Xu L, Pan K, et al. ETV5 regulates hepatic fatty acid metabolism through PPAR signaling pathway. Diabetes 2021;70:214–226.

[27] Utema M, Plagnol V, Li K, Whittall RA, Neil HA, Seed M, et al. Whole exome sequencing of familial hypercholesterolemia patients negative for LDLR/ABO/PCSK9 mutations. J Med Genet 2014;51:537–544.

[28] Araya J, Rodrigro R, Videla LA, Thielemann L, Orelana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n - 6 to n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004;106:635–643.

[29] Elizondo A, Araya J, Rodrigro R, Ponjachik J, Csendes A, Maluenda F, et al. Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity (Silver Spring) 2007;15:24–31.

[30] Pettinelli P, Del Pozo T, Araya J, Rodrigro R, Araya AV, Smok G, et al. Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 2000;1792:1080–1086.

[31] Liu D, Wong CC, Fu L, Chen H, Zhao I, Li C, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med 2018;10:eaaq9840.

[32] Dutkowski P, Linecker M, DeOliveira ML, Mullhaupt B, Clavien PA. Challenges of liver transplantation and strategies to improve outcomes. Gastroenterology 2015;148:307–323.

[33] McCormack L, Petsowky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007;245:923–930.

[34] Romeo S, Kozlitina J, Xing C, Pertsemidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461–1465.

[35] Geisler CE, Hepler C, Higgins MR, Renquist BJ. Hepatic adaptations to maintain metabolic homeostasis in response to fasting and refeeding in mice. Nutr Metab 2016;13:62.

[36] Andrikopoulos S, Massa CM, Astron-Mourney K, Funtak A, Farn BC, Hull RL, et al. Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on hepatic synthesis and dysregulation of cholesterol metabolism in response to fasting and refeeding in mice. Nutr Metab 2016;13:62.

[37] Wang WY, Rolebro J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clin Nutr 2019;38:975–981.

[38] Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol 2017;15:474–485.

[39] Teufel A, Izlet T, Erhart W, Borsch M, Wang XY, KIm YO, et al. Comparison of Gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. Gastroenterology 2016;151:513–525.